New treatment options have changed the survival of patients with follicular lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 33, 2005, Pages 8447-8452

  Fisher, Richard L ^a   LeBlanc, Michael ^a   Press, Oliver W ^a   Maloney, David G ^a   Unger, Joseph M ^a   Miller, Thomas P ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERFERON; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; FOLINIC ACID; MONOCLONAL ANTIBODY; MOPP PROTOCOL; PROMACE PROTOCOL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LEUCOVORIN; LYMPHOMA, FOLLICULAR; MALE; MECHLORETHAMINE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES; VINCRISTINE;

EID: 33644677932     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.1674     Document Type: Article

References (18)

1. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
2. Fisher RI, Dana B, LeBlanc M, et al: Alpha-interferon consolidation following intensive chemotherapy does not prolong the progression-free survival of patients with low grade non-Hodgkin's lymphoma: Results of SWOG-8809, a randomized phase III study. J Clin Oncol 18:2010-2016, 2000
3. Maloney DG, Press OW, Braziel RM, et al: A phase II trial of chop followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800. Blood 98:843a, 2001 (abstr 3502)
4. Press OW, Unger JM, Braziel RM, et al: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612, 2003
5. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
6. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
7. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
8. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
9. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993 (suppl 5)
10. Solal-Celigny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993
11. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon alpha combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992
12. Rohatmer AZ, Gregory WM, Peterson B, et al: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215-2223, 2005
13. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage-The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982
14. Harris NL, Jaffe ES, Stein H, et al: Perspective: A Revised European-American Classification of Lymphoid Neoplasm-A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
15. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Arlie House, Virginia, November, 1997. J Clin Oncol 17:3835-3849, 1999
16. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine 1311 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
17. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
18. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-Year follow-up. J Clin Oncol 22:4711-4716, 2004